Generic Name and Formulations:
Droxidopa 100mg, 200mg, 300mg+; capsules; (+) contains tartrazine.
Indications for NORTHERA:
Symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Swallow whole. Take with or without food. Initially 100mg three times daily in the morning, midday, and late afternoon (≥3hrs prior to bedtime). Titrate in increments of 100mg three times daily every 24–48hrs; max 600mg three times daily.
May cause or exacerbate supine hypertension. Monitor BP (supine and head-elevated sleeping positions) prior to initiating and after increasing the dose; reduce dose or discontinue if supine hypertension persists. Monitor for symptoms of neuroleptic malignant syndrome; observe carefully during dose changes or when concomitant levodopa is reduced abruptly or discontinued, especially if receiving neuroleptics. May exacerbate ischemic heart disease, arrhythmias, CHF. Discontinue if hypersensitivity reactions occur. Allergic reactions (tartrazine). Reevaluate periodically. Severe renal impairment (GFR <30mL/min): limited data. Pregnancy. Nursing mothers: not recommended.
Concomitant drugs that increase BP (eg, norepinephrine, ephedrine, midodrine, and triptans); increased risk of supine hypertension. Concomitant dopa-decarboxylase inhibitors: may need to adjust droxidopa dose. Avoid concomitant non-selective MAOIs or linezolid.
Headache, dizziness, nausea, hypertension, falls, UTI, syncope; hyperpyrexia, confusion.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes